Table 5 Description of antiangiogenic treatment, according to PCDT recommendation, of AMD-patients in the Brazilian public health system
Brazil | North | Northeast | Central-West | Southeast | South | |
|---|---|---|---|---|---|---|
AMD patients with at least one antiangiogenic therapy, N (%) | 1460 | 0 | 4 (0.2) | 55 (3.7) | 1129 (77.3) | 272 (18.6) |
Doses of antiangiogenic therapy per patient, median (IQR) | 2 (1-3) | – | 2 (1-4) | 2 (1-3) | 2 (1-3) | 3 (1-4) |
Doses strata, N (%) | ||||||
≤ 2 doses | 866 (59.3) | – | 2 (50.0) | 36 (65.5) | 698 (61.8) | 130 (47.8) |
3 – 4 doses | 496 (34.0) | – | 1 (25.0) | 17 (30.9) | 380 (33.6) | 98 (36.0) |
5 – 6 doses | 76 (5.2) | – | 0 (0.0) | 2 (3.6) | 41 (3.6) | 33 (12.1) |
7 – 8 doses | 17 (1.2) | – | 1 (25.0) | 0 (0.0) | 8 (0.7) | 8 (2.9) |
≥ 9 doses | 5 (0.3) | – | 0 (0.0) | 0 (0.0) | 2 (0.02) | 3 (1.1) |
Interval-time between doses of antiangiogenic therapy (days), median (IQR) | 31 (28-61) | – | 45.5 (30.75-66.5) | 39 (34.25-69.5) | 35 (30-61) | 28 (19-39) |
Interval-time strata, N (%) | ||||||
< 20 days | 174 (12.7) | – | 0 (0.0) | 3 (6.0) | 37 (4.6) | 134 (26.3) |
20 – 40 days | 704 (51.5) | – | 2 (50.0) | 25 (50.0) | 427 (53.1) | 250 (49.1) |
40 – 60 days | 134 (9.8) | – | 1 (25.0) | 4 (8.0) | 72 (9.0) | 57 (11.2) |
60 – 80 days | 143 (10.4) | – | 0 (0.0) | 6 (12.0) | 117 (14.6) | 20 (3.9) |
80 – 100 days | 50 (3.6) | – | 1 (25.0) | 2 (4.0) | 39 (4.9) | 8 (1.6) |
> 100 days | 161 (11.7) | – | 0 (0.0) | 10 (20.0) | 111 (13.8) | 40 (7.9) |